$695 | Single User
$1395 | Global License

Physician Views: The return of inhaled insulin – a paradigm shift or hard sell?
[Lowest Price Guaranteed: $695]

Published by FirstWord Pharma: 13 Feb 2015 | 189 | In Stock
Related Topics: Pfizer

Introduction

Scope



Sanofi is currently in the process of launching Afrezza in the US market. Afrezza is an inhaled insulin developed by MannKind, which was in-licensed by Sanofi last year. It is the first inhaled insulin to be made available since Pfizer launched Exubera in the US in September 2006. Due to poor uptake, Exubera was withdrawn from the market in October 2007.


Both Exubera and Afrezza have demonstrated comparable, but not superior, efficacy to injectable insulin. Commercial failure of Pfizer's product was driven in part by additional cost (for the patient/payer) and the large inconvenient device that was used to administer Exubera.


MannKind and Sanofi have sought to circumvent these issues: Afrezza is delivered via a small, whistle-sized device and has a list price of between 5 and 0 for a 30-day supply of 90 cartridges. Assuming a typical level of rebates and discounts, analysts do not expect this price to act as a major obstacle to access.


Challenges are nevertheless expected to lie ahead. These include likely broad tier-3 formulary status at launch and the view among some analysts that endocrinologists will not proactively prescribe Afrezza, but instead wait for patients to request the drug (which in turn will increase necessary investment in promotion of the franchise).


When FirstWord polled 52 endocrinologists last April (shortly after Afrezza had gained a positive Advisory Committee recommendation), a key concern among physicians was the side-effect risk associated with inhalation. Around half of all respondents indicated that potential long-term pulmonary and cancer risks – an issue also discussed in depth during the AdCom – would act as the main reason for them not using Afrezza. Around a third of endocrinologists suggested that a likely lack of real-world efficacy versus injectable insulin would act as the main deterrent.


Sanofi's launch strategy for Afrezza is focused on two groups of diabetes patients: Those who are potential insulin users who do not currently use insulin because of a dislike of injections and those who use basal insulin, but are naïve to short-acting insulin and require an 'intensification' of therapy at mealtimes.


Patient feedback cited by Sanofi in recent investor presentations indicates a potentially sizeable population who are discouraged to initiate insulin therapy due to injectable administration, while physician feedback sourced by FirstWord indicates that patients with needle phobia represent the obvious target for Afrezza.


While Sanofi suggests that around 40 percent of potential insulin users are not using insulin because of a dislike of injections, translating this into an 'actionable' driver for uptake of Afrezza will nevertheless be challenging. Not only does anecdotal evidence indicate that many patients who are initially cautious towards self-injection quickly become adept at the practice, but the proportion of true needle-phobic patients is much lower.


With physicians already indicating that patients who are adverse to the idea of injection are likely to act as the most prominent users of Afrezza, it also remains to be seen how much traction Sanofi can achieve in those patients who need an intensification of therapy, but whom already inject basal insulin.


Puchase Reasons


To better ascertain how the initial launch of Afrezza is likely to progress, and whether Sanofi's strategy appears feasible, FirstWord is polling US and EU-5 based endocrinologists this week (Sanofi is due to submit the drug for approval in Europe shortly). Specifically we are asking them…


Versus your experience in the real-world setting, what is your assessment of the suggestion that there are a significant proportion of potential insulin users – 40 percent – who are not currently using insulin because of a dislike of injections?

  • This figure is very low

  • This figure is moderately low

  • This figure is marginally low

  • This figure is accurate

  • This figure is marginally high

  • This figure is moderately high

  • This figure is very high

  • Is it fair to suggest that the majority of patients who are initially sceptical of self-injecting insulin quickly become adept at the practice?

  • Completely disagree

  • Disagree

  • Somewhat disagree

  • Neither agree or disagree

  • Somewhat agree

  • Agree

  • Completely agree

  • Patients who already self-inject basal insulin, but who require intensification with a short-acting insulin at mealtimes, represent a significant opportunity for use of Afrezza?

  • Completely disagree

  • Disagree

  • Somewhat disagree

  • Neither agree or disagree

  • Somewhat agree

  • Agree

  • Completely agree

  • Do you plan to actively prescribe Afrezza unless a patient specifically requests it?

  • No – will not prescribe under any circumstances

  • No – would recommend against prescribing

  • No – would prescribe readily if patient requests

  • Yes – slight use

  • Yes – moderate use

  • Yes – very high use

  • Yes – Extremely high use

  • Afrezza meets a significant unmet need in the insulin market?

  • Completely disagree

  • Disagree

  • Somewhat disagree

  • Neither agree or disagree

  • Somewhat agree

  • Agree

  • Completely agree
  • Table of Contents
    for Physician Views: The return of inhaled insulin – a paradigm shift or hard sell?

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    189 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: The return of inhaled insulin – a paradigm shift or hard sell? | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...